# AmerisourceBergen Corporation (ABC) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/ABC/financials · /stocks/ABC/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/ABC/memo ($2.00, Bearer token).

## Business Model

---
source: coverage-next-full
type: step_output
step: 01
ticker: ABC
company: Cencora, Inc.
sector: Health Care
generated: 2026-05-27
---

### Step 01 — Business Overview: Cencora, Inc. (COR)

#### 1. Company Summary

Cencora (formerly AmerisourceBergen) is the second-largest pharmaceutical distributor in the United States by revenue, and one of the largest healthcare services companies globally. Founded in 2001 from the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, the company rebranded to Cencora in August 2023 to better reflect its expanded, globally integrated identity [S1].

In FY2025 (fiscal year ended September 30, 2025), Cencora generated $321.3 billion in revenue, making it one of the largest companies in the world by revenue — roughly the GDP of a small-to-medium-sized nation. Yet its business is fundamentally one of logistics: moving pharmaceutical products through the supply chain as efficiently and reliably as possible, earning thin margins on massive volume.

The core business model: drug manufacturers produce medications and need to distribute them to the end points of care — pharmacies, hospitals, physician offices, clinics. Cencora sits as the intermediary, taking physical and economic ownership of drugs, warehousing them in temperature-controlled distribution centers, and delivering them rapidly and reliably. Manufacturers pay service fees (per-unit fees, data fees, logistics fees) and Cencora earns the spread between purchase price and sale price, with the spread driven largely by generic drug purchasing power and specialty distribution margins [S2].

#### 2. Segment Structure

##### U.S. Healthcare Solutions (90.6% of FY2025 Revenue)

Revenue: $291.0B (FY2025), +9.7% YoY

The U.S. segment is divided into:

**U.S. Human Health ($285.3B, +9.7%):**
- Traditional pharmaceutical distribution to retail pharmacies (Walgreens is the largest customer), health systems, clinics, and specialty physician practices
- Specialty distribution (AmerisourceBergen Specialty Group / ABSG): Oncology, retina (post-RCA acquisition January 2025), neurology, rheumatology, dermatology — drugs dispensed directly in physician offices
- Manufacturer services: Clinical trial support, commercialization support, packaging, pharmacy management
- GLP-1 products: Became a dominant driver; +26.9% growth (+$7.7B) in FY2025 [S1]
- OneOncology (acquired February 2026): ~500+ physician practices, community oncology platform; adds further specialty depth

**U.S. Animal Health ($5.7B, +6.1%):**
- MWI Veterinary Supply: Distributes pharmaceuticals and products to companion animal and production animal markets
- Now classified as "Other" starting FY2026 as management explores strategic alternatives

**Retina Consultants of America (RCA):**
- Acquired January 2025 for ~$3.9B cash; ~85% Cencora ownership
- 200+ affiliated retina practices; largest retinal specialty practice network in U.S.
- Added significantly to FY2025 gross profit (+23% U.S. GP, driven by RCA)
- Classified within U.S. Human Health

##### International Healthcare Solutions (9.4% of FY2025 Revenue)

Revenue: $30.4B (FY2025), +6.1% YoY

**Alliance Healthcare ($24.4B, +5.8%):**
- Pan-European pharmaceutical distributor; acquired 2021 for ~$6.5B
- Operations in UK, Spain, Germany, Portugal, Turkey, and other European markets
- Standard pharmaceutical distribution with some retail pharmacy network
- Higher GP margin (~10-11%) than U.S. distribution business

**Other International Healthcare Solutions ($6.0B, +7.3%):**
- **World Courier:** Global specialty pharmaceutical logistics for clinical trials and biopharma
- **PharmaLex:** Regulatory affairs, pharmacovigilance, development consulting for life sciences (acquired January 2023; $1.4B; now subject to goodwill impairments — $418M FY2024, $724M FY2025)
- **Innomar Strategies (Canada):** Specialty pharmaceutical services
- **Profarma (Brazil):** Full-line pharmaceutical distribution (less-than-wholly-owned)

#### 3. Value-Chain Position

```
MANUFACTURER → [Cencora] → HEALTHCARE PROVIDER → PATIENT
                    ↓
         Distribution Centers (~30 in U.S.)
         Temperature-controlled warehousing
         Track-and-trace serialization
         Credit and payment terms management
         Returns management
```

Cencora sits between ~1,500+ pharmaceutical manufacturers and ~100,000+ healthcare provider customers. This intermediary position generates several types of economic value:

1. **Logistics efficiency:** Manufacturers need not maintain direct-to-provider networks; Cencora's scale is irreplaceable
2. **Working capital intermediary:** Cencora extends credit to pharmacies and health systems, funded by supplier payment terms from manufacturers; the difference in DPO (60 days) vs. DSO (28 days) creates working capital float
3. **Data and analytics:** Purchase data from across the supply chain is monetized via manufacturer consulting and analytics services
4. **Specialty access:** In specialty segments, Cencora provides REMS program support, reimbursement services, and patient adherence tools that manufacturers cannot easily replicate

#### 4. Revenue Model

| Revenue Type | Estimated % of Revenue | Margin Profile |
|-------------|------------------------|----------------|
| Brand pharmaceutical distribution | ~60-65% | Very thin (~1-2% GP margin) |
| Generic pharmaceutical distribution | ~15-20% | Higher (~4-6% GP margin) |
| Specialty pharmaceutical distribution | ~8-12% | Best (~5-8% GP margin) |
| RCA / physician services | ~2-3% | High (~40%+ service margin) |
| International (Alliance Healthcare) | ~7-8% | Medium (~10-11% GP margin) |
| Other (World Courier, PharmaLex, etc.) | ~2-3% | Variable |

#### 5. Customer Concentration

- Top 2 customers represent ~37% + ~5% of accounts receivable (per FY2024 10-K) [S2]
- Walgreens Boots Alliance (WBA) is widely understood to be the largest customer
- Second-largest is likely Express Scripts / Evernorth (Cigna subsidiary); supply agreement extended through September 2029
- Healthcare system customers (hospital groups, IDNs) represent a growing and diversifying base
- GLP-1 pharmacy concentration: Significant sales to WBA and mail-order customers

#### 6. Key Business Metrics (FY2025)

| KPI | Value |
|-----|-------|
| Revenue | $321.3B |
| Gross Profit | $11.5B (3.57% margin) |
| U.S. Healthcare Solutions Operating Income | $3.57B (1.23% margin) |
| International Operating Income | $648M (~2.1% margin) |
| Operating Cash Flow | $3.9B |
| Free Cash Flow (est.) | ~$3.2B |
| Days Sales Outstanding (DSO) | 27.9 days |
| Days Inventory on Hand (DIOH) | 27.0 days |
| Days Payable Outstanding (DPO) | 59.6 days |
| Shares Outstanding | ~190M (est.) |

#### Source Index

| ID | Source |
|----|--------|
| S1 | Cencora FY2025 10-K (Sep 30, 2025), EDGAR |
| S2 | Cencora FY2024 10-K (Sep 30, 2024), EDGAR |
| S3 | Cencora Q2 FY2026 10-Q (Mar 31, 2026), EDGAR |

## Recent Catalysts

---
source: coverage-next-full
type: step_output
step: 12
ticker: ABC
company: Cencora, Inc.
sector: Health Care
generated: 2026-05-27
---

### Step 12 — Bull/Bear: Cencora, Inc. (COR)

**Note on Methodology:** This step was produced using the filings-and-consensus path (coverage-next-full). Earnings transcripts were not loaded; the bull/bear debate is inferred from consensus analyst commentary, MD&A language, press releases, and Tavily research. The analyst debate structure follows the Step 12 framework as adapted for the filings-only path.

---

#### Current Situation (May 2026)

Cencora (COR) is trading at ~$265/share, down ~27% from its 52-week highs (~$370-400) recorded in early 2026 before the Q2 FY2026 results (May 6, 2026). The Q2 FY2026 results were a mixed quarter: adjusted EPS beat ($4.75 vs. $4.73), but revenue fell slightly short and management cited customer losses (oncology, grocery) and GLP-1 growth deceleration. Multiple analyst price target cuts followed (Evercore: $300-$360→$300; Citi: $355-$405→$355), but Barclays reiterated Buy and UBS raised its target to $412 [S5].

The company trades at ~15x FY2026E adjusted EPS of $17.65-$17.90 guidance. Consensus implies 29.8% upside from current levels [S5].

---

#### Bull Case

**Bull Thesis Statement:** Cencora is a durable oligopolist executing a strategically sound expansion into high-margin specialty physician services (RCA retina + OneOncology) that will compound adjusted EPS at 8-12% annually for the next 5 years, with the stock's current discount to fair value (~30%) representing a compelling entry for long-duration capital.

**Bull Bullet 1: Specialty Expansion Directly Addresses the Margin Ceiling**
The historical knock on pharmaceutical distributors is that gross margins are structurally capped at 2-3.5% (thin logistics economics). Cencora's RCA and OneOncology acquisitions directly attack this ceiling by embedding within physician practices that buy-and-bill specialty drugs at 30-50% gross margins. In just FY2025, RCA alone drove U.S. Healthcare Solutions GP margin to 2.72% (+30 bps) and U.S. segment operating income to $3.57B (+21.8%). OneOncology adds a much larger specialty network (~500+ physicians) that will further expand margins as it integrates. At maturity, Cencora could sustain 3-4% consolidated GP margins vs. the 2.4% it was earning in FY2022 [S1].

**Bull Bullet 2: GLP-1 Secular Tailwind Has Years of Runway**
GLP-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are generating the pharmaceutical industry's largest-ever product cycles. Cencora grew GLP-1 revenue by $8.6B (+43%) in FY2024 and $7.7B (+27%) in FY2025. While H1 FY2026 growth has slowed to +16-23%, the absolute dollar growth (~$2B in a single quarter) remains massive. IQVIA forecasts the U.S. pharmaceutical market to grow at 8.2% CAGR through 2028, with GLP-1 as a primary driver. As GLP-1 indications expand (obesity, cardiovascular, CKD, sleep apnea), the total addressable market grows beyond the ~$45B current estimated annual run rate. Cencora is the distribution infrastructure for this secular trend [S1].

**Bull Bullet 3: $265 Represents a Historically Discounted Multiple on Durable Earnings Power**
At $265, COR trades at ~15x FY2026E adjusted EPS of $17.75 midpoint. The five-year adjusted EPS CAGR has been ~15%+ (from ~$10 in FY2021 to $17.75E in FY2026). Consensus expects ~$19.77 in FY2027E EPS (+11% growth), implying a forward P/E of only ~13x — historically cheap for a business with 20%+ ROIC on invested capital, durable oligopolistic position, and expanding specialty margins. Historical 5-year average P/E for COR has been ~18-22x. If multiples simply normalize to 17-18x on $19.77 FY2027 EPS, the stock is worth $336-$356, representing 26-34% upside [S5, S6].

---

#### Bear Case

**Bear Thesis Statement:** Cencora is an oligopolistic distributor that has over-leveraged its balance sheet (~$18B net debt) through a string of expensive acquisitions (PharmaLex failed; RCA and OneOncology's ROICs are uncertain), while its core U.S. revenue growth decelerates to 3-4% as GLP-1 growth normalizes, customer losses compound, and WBA's financial fragility threatens the single largest customer relationship.

**Bear Bullet 1: The M&A Treadmill Is Destroying Capital**
Cencora has deployed ~$11B+ of capital in 13 months (RCA $3.9B + OneOncology $7.4B FV), on top of the $1.4B PharmaLex write-off. PharmaLex — acquired for $1.4B, impaired by $1.14B in just 2 years — shows the management team can overpay significantly for professional services acquisitions. OneOncology was purchased at $7.4B fair value for a community oncology network. If OneOncology follows PharmaLex's trajectory (integration difficulties, consulting/professional services harder to manage than distribution), another multi-billion goodwill impairment cycle could be ahead. Combined impairments over FY2024-FY2025 were $1.14B; FY2026 adds equity investment impairment. Balance sheet goodwill risk is rising [S1, S2].

**Bear Bullet 2: WBA Customer Risk Is Underappreciated**
WBA represents Cencora's largest single customer relationship, with supply agreement through 2029. WBA is closing thousands of stores, reporting operating losses in its U.S. pharmacy segment, and has been in financial distress for several years. If WBA's store closures are significant enough to reduce total pharmacy prescription volume (not merely shifting prescriptions to surviving WBA or other pharmacies), Cencora faces a structural revenue headwind. Furthermore, if WBA explores bankruptcy or a sale, contract renegotiation could reduce pricing or terms for Cencora. The top-2 customers represent ~42% of AR — this concentration is a vulnerability that the Street may be underpricing given current optimism around specialty expansion [S2].

**Bear Bullet 3: Revenue Deceleration + Elevated Leverage = Multiple Compression Risk**
H1 FY2026 revenue growth of 4.7% is a sharp deceleration from FY2024's 12.1% and FY2025's 9.3%. Customer losses (oncology, grocery), GLP-1 growth normalization (from 43% to 23% to potentially mid-teens), and brand drug price deflation are all converging. Meanwhile, net debt has risen to ~$15-18B (from ~$4B in FY2023), interest expense has nearly doubled to ~$420M (FY2025) and will rise further in FY2026. If revenue growth settles at 4-6% vs. the double-digit rates of FY2024-FY2025, the Street may re-rate the stock to 12-13x earnings (lower for a decelerating compounder), implying downside to $210-$230 from current $265 [S5].

---

#### Conclusion

The current $265 stock price represents a significant sell-off from highs and embeds material pessimism about near-term GLP-1 and U.S. growth normalization. The bull case is better supported by the long-term specialty thesis and durable oligopolistic moat. The bear case has merit primarily around the M&A-induced leverage and WBA concentration risk. The most important near-term signposts are:
1. FY2026 Q3 (April–June 2026) revenue and GP margin — will OneOncology contribution show in results?
2. WBA pharmacy prescription volumes — any public disclosure of volume trends
3. GLP-1 prescription data — IQVIA monthly data on semaglutide/tirzepatide prescriptions

#### Source Index

| ID | Source |
|----|--------|
| S1 | Cencora FY2025 10-K, EDGAR |
| S2 | Cencora FY2024 10-K, EDGAR |
| S3 | Cencora Q2 FY2026 10-Q, EDGAR |
| S4 | `other/consensus.md` |
| S5 | Tavily search — analyst ratings, price targets, consensus estimates |
| S6 | Valuation estimates from consensus.md |

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/ABC/memo

## Navigation

- Overview: /stocks/ABC
- Financials: /stocks/ABC/financials
- Thesis (this page): /stocks/ABC/thesis
- Investment Memo: /stocks/ABC/memo
- Coverage universe: /stocks